Key Highlights
- Shares trading down 0.66% to $17.38 in today's session.
- Trading Volume reached 9.02 million shares.
- The company reported a trailing P/E ratio of 6.63 and an EPS of $2.52.
- The deal is expected to be immediately accretive to the company's financial guidance.
Viatris to Acquire Pacira for $1.65 Billion in Cash
Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed in 2020 through the Merger of Mylan and Pfizer's Upjohn division, agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing the deal at approximately $1.65 billion. The Acquisition will be carried out through a tender offer followed by a merger, with closing expected by the end of 2026.
Deal Adds Established Non-Opioid Pain Products
The acquisition brings two established, patent-protected products into the company's portfolio, EXPAREL for postsurgical pain and ZILRETTA for knee osteoarthritis pain, which together generated roughly $746 million in Revenue and $177 million in adjusted EBITDA over the past year. Management said the products are synergistic with its existing fast-acting meloxicam opportunity in non-opioid pain management.
Shares Dip Slightly in a Typical Acquirer Reaction
Shares slipped modestly today, with a trailing P/E ratio of 6.63 and an EPS of $2.52 reflecting the company's established, profitable base business. The company said it expects to fund the transaction primarily from excess cash, with minimal impact on its gross leverage ratio, and that the deal should be immediately accretive to its financial guidance metrics.
Outlook: Deal Expected to Close by Year-End
The transaction remains subject to a majority tender of Pacira shares and regulatory clearance, with closing expected by the end of 2026. The company's third-quarter results, scheduled for early November, may provide further detail on how the deal fits into its broader Long-term Growth targets.
FAQs
Q: Why did Viatris stock dip today?
A: Shares fell 0.66% after the company announced it would acquire Pacira BioSciences for approximately $1.65 billion in cash, a typical reaction for an acquirer taking on new spending.
Q: What products does the deal add to Viatris?
A: The deal adds EXPAREL and ZILRETTA, two non-opioid pain management products that generated about $746 million in revenue over the past year.
Q: How will Viatris fund the acquisition?
A: The company expects to fund the transaction primarily from excess cash, with the remainder from short-term borrowings, resulting in minimal impact on its gross leverage ratio.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.